ClinicalTrials.gg

Program

precemtabart tocentecan

Also written as “M9140” and “Precemtabart tocentecan”.

Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms, led by Merck KGaA, Darmstadt, Germany.

Furthest: phase 3, since Apr 16, 20264 company-led studies, 3 open or runningNext primary completion: Dec 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany43 open or runningphase 3since Apr 16, 2026Jul 15, 2022Dec 23, 2027phase 2 · NCT06710132

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 15, 2022First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT05464030 · 220 enrolled · United States, Canada, Japan and more
  2. Nov 22, 2024Phase 2 study in Stomach NeoplasmsNCT06710132 · 184 enrolled · United States, Australia, Austria and more
  3. Jan 13, 2025Phase 1 study in Colorectal NeoplasmsNCT06806046 · 12 enrolled · China
  4. Apr 16, 2026Phase 3 study in Colorectal NeoplasmsPhase 3 reachedNCT07549412 · 1,020 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 23, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT06710132
  2. Oct 16, 2029Primary completion: phase 3 study in Colorectal NeoplasmsNCT07549412

TargetBeta

CEACAM5 →read by rule
“An antibody-drug conjugate (ADC) composed of precemtabart, a human immunoglobulin G1-kappa monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA), ”NCIt, by rule

Other programs on CEACAM5

ProgramCompanyFurthest phaseStudies
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceuticalphase 22
Anti-CEACAM5 Antibody-drug Conjugate BMS-986490ruleBristol-Myers Squibbphase 21
Anti-CEACAM5 Antibody-drug Conjugate IBI3020ruleInnovent Biologicsphase 11
tusamitamab sonditecanPfizerphase 11
RO7821657ruleHoffmann-La Rochephase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07549412Colorectal Neoplasms · United States, Argentina, Australia and more3RecruitingOct 16, 20291,020
NCT06806046Colorectal Neoplasms · China1CompletedSep 23, 202612
NCT06710132Stomach Neoplasms · United States, Australia, Austria and more2Active, not recruitingDec 23, 2027184
NCT05464030Colorectal Neoplasms · United States, Canada, Japan and more1Active, not recruitingOct 23, 2026220

How it is read

Names in the registry

  • “M9140”, 4 entries
  • “Precemtabart tocentecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.